1. Home >
  2. M&A >
  3. Stake Purchase >
  4. China >
  5. bioMerieux Invests In Suzhou Hybiome Biomedical Engineering Co.

Investment Summary

bioMerieux Invests In Suzhou Hybiome Biomedical Engineering Co.

On November 9, 2018, bioMerieux invested in medical products company Suzhou Hybiome Biomedical Engineering Co.

Investment Highlights
  • This is bioMerieux’s 7th transaction in the Medical Products sector.
  • This is bioMerieux’s 3rd transaction in China.

Investment Summary
Date 2018-11-09
Target Suzhou Hybiome Biomedical Engineering Co.
Sector Medical Products
Investor(s) bioMerieux
Deal Type Stake Purchase

Target

Suzhou Hybiome Biomedical Engineering Co.

Suzhou, China
Suzhou Hybiome Biomedical Engineering Co.Ltd. is specialized in automated immunoassay tests. The company develops, manufactures and markets a complete range of diagnostic solutions (reagents, instruments, and software) cleared by the China Food and Drug Administration (CFDA). Hybiome markets two automated, mid-throughput immunoassay systems (AE-180 and AE-240) using the latest generation CLIA1 technology and featuring a menu of nearly 80 parameters. Hybiome also recently received CFDA clearance for the AE-120 system, to further increase access to its menu of assays. Hybiome’s installed base has about 1,000 active instruments that are used primarily in medium-sized hospitals (100 to 500 beds), known as Grade 2 facilities.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

bioMerieux

Marcy l'Etoile, France
Category Company
Founded 1963
Sector Life Science
Employees14,147
Revenue 4.0B EUR (2024)
DESCRIPTION

bioMerieux is a provider in the field of in vitro diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening, monitoring, and cardiovascular emergencies. bioMerieux was founded in 1963 and is based in Marcy-l'Étoile, France.

DEAL STATS #
Overall 19 of 21
Sector: Medical Products M&A 7 of 9
Type: Stake Purchase M&A Deals 1 of 1
Country: China M&A 3 of 3
Year: 2018 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-05 Applied Maths NV

Sint-Martens-Latem, Belgium

Applied Maths NV a company that develops state-of-the-art software solutions for the biosciences, in particular for databasing, analysis and interpretation of complex biological data. Applied Maths develops and commercializes BioNumerics universal software for microbiology applications, including in bacteriology, virology and mycology.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-02-07 Invisible Sentinel

Philadelphia, Pennsylvania, United States

Invisible Sentinel, Inc. develops, manufactures and markets innovative and user-friendly molecular diagnostic tools for the rapid, accurate and reliable detection of pathogens and spoilage organisms in food and beverage.

Buy $75M
Mergr

Solution for

Product

Company

Legal